Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)
Public ClinicalTrials.gov record NCT02718326. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients With Moderately Severe to Severe Nonproliferative Diabetic Retinopathy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study is to assess the efficacy of intravitreal (IVT) aflibercept compared to sham treatment in the improvement of moderately severe to severe nonproliferative diabetic retinopathy (NPDR). The secondary objectives of the study are: * To characterize the safety of IVT aflibercept in patients with moderately severe to severe NPDR * To determine if IVT aflibercept will prevent the worsening of diabetic retinopathy and reduce the incidence of DME * To determine the anatomic effects of IVT aflibercept in patients with moderately severe to severe NPDR
Study identification
- NCT ID
- NCT02718326
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 402 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 29, 2016 (Actual)
- Primary completion
- Aug 6, 2018 (Actual)
- Completion
- Jul 16, 2019 (Actual)
- Last update posted
- Jul 30, 2020
2016 – 2019
United States locations
- U.S. sites
- 71
- U.S. states
- 28
- U.S. cities
- 66
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Regeneron Study Site | Phoenix | Arizona | 85020 | — |
| Regeneron Study Site | Tucson | Arizona | 85704 | — |
| Regeneron Study Site | Arcadia | California | 91007 | — |
| Regeneron Study Site | Beverly Hills | California | 90211 | — |
| Regeneron Study Site | Encino | California | 91436 | — |
| Regeneron Study Site | Fullerton | California | 92835 | — |
| Regeneron Study Site | La Jolla | California | 92093 | — |
| Regeneron Study Site | Mountain View | California | 94040 | — |
| Regeneron Study Site | Oakland | California | 94609 | — |
| Regeneron Study Site | Oceanside | California | 92056 | — |
| Regeneron Study Site | Sacramento | California | 95841 | — |
| Regeneron Study Site | Colorado Springs | Colorado | 80909 | — |
| Regeneron Study Site | Golden | Colorado | 80401 | — |
| Regeneron Study Site | New London | Connecticut | 06320 | — |
| Regeneron Study Site | Altamonte Springs | Florida | 32701 | — |
| Regeneron Study Site | Deerfield Beach | Florida | 33064 | — |
| Regeneron Study Site | Fort Myers | Florida | 33912 | — |
| Regeneron Study Site | Lakeland | Florida | 33805 | — |
| Regeneron Study Site | Largo | Florida | 33770 | — |
| Regeneron Study Site | Melbourne | Florida | 32901 | — |
| Regeneron Study Site | Miami | Florida | 33126 | — |
| Regeneron Study Site | Miami | Florida | 33143 | — |
| Regeneron Study Site | Orlando | Florida | 32806 | — |
| Regeneron Study Site | Plantation | Florida | 33324 | — |
| Regeneron Study Site | Tallahassee | Florida | 32308 | — |
| Regeneron Study Site | Tampa | Florida | 33612 | — |
| Regeneron Study Site | Winter Haven | Florida | 33880 | — |
| Regeneron Study Ssites | Marietta | Georgia | 30060 | — |
| Regeneron study Site | Tucker | Georgia | 30084 | — |
| Regeneron Study Site | Chicago | Illinois | 60612 | — |
| Regeneron Study Site | Oak Forest | Illinois | 60452 | — |
| Regeneron Study Site | Indianapolis | Indiana | 46290 | — |
| Regeneron Study Site | New Albany | Indiana | 47150 | — |
| Regeneron Study Site | Lexington | Kentucky | 40509 | — |
| Regeneron Study Site | Baltimore | Maryland | 21204 | — |
| Regeneron Study Siste | Baltimore | Maryland | 21209 | — |
| Regeneron Study Site | Baltimore | Maryland | 21287 | — |
| Regeneron Study Site | Hagerstown | Maryland | 21740 | — |
| Regeneron Study Site | Boston | Massachusetts | 02114 | — |
| Regeneron Study Site | Henderson | Nevada | 89052 | — |
| Regeneron Study Site | Bloomfield | New Jersey | 07003 | — |
| Regeneron Study Site | Albuquerque | New Mexico | 87109 | — |
| Regeneron Study Site | Asheville | North Carolina | 28803 | — |
| Regeneron Study Site | Charlotte | North Carolina | 28210 | — |
| Regeneron Study Site | Columbus | Ohio | 43212 | — |
| Regeneron Study Site | Oklahoma City | Oklahoma | 73104 | — |
| Regeneron Study Site | Medford | Oregon | 97504 | — |
| Regeneron Study Site | Kingston | Pennsylvania | 18704 | — |
| Regeneron Study Site | Philadelphia | Pennsylvania | 19107 | — |
| Regeneron Study Site | Florence | South Carolina | 29501 | — |
| Regeneron Study Site | Ladson | South Carolina | 29456 | — |
| Regeneron Study Site | West Columbia | South Carolina | 29169 | — |
| Regeneron Study Site | Rapid City | South Dakota | 57701 | — |
| Regeneron Study Site | Chattanooga | Tennessee | 37421 | — |
| Regeneron Study Site | Germantown | Tennessee | 38138 | — |
| Regeneron Study Site | Nashville | Tennessee | 37203 | — |
| Regeneron Study Site | Nashville | Tennessee | 37232 | — |
| Regeneron Study Site | Abilene | Texas | 79606 | — |
| Regeneron Study Site 1 | Austin | Texas | 78705 | — |
| Regeneron Study Site 2 | Austin | Texas | 78705 | — |
| Regeneron Study Site | Dallas | Texas | 75231 | — |
| Regeneron Study Site | Harlingen | Texas | 78559 | — |
| Regeneron Study Site | Houston | Texas | 77030 | — |
| Regeneron Study Site | San Antonio | Texas | 78240 | — |
| Regeneron Study Site | The Woodlands | Texas | 77384 | — |
| Regeneron Study Site | Willow Park | Texas | 76087 | — |
| Regeneron Study Site | Salt Lake City | Utah | 84132 | — |
| Regeneron Study Site | Burlington | Vermont | 05401 | — |
| Regeneron Study Site | Fairfax | Virginia | 22031 | — |
| Regeneron Study Site | Spokane | Washington | 99204 | — |
| Regeneron Study Site | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02718326, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 30, 2020 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02718326 live on ClinicalTrials.gov.